© Reuters.
InspireMD (NASDAQ:) Inc has reported a strong Q3 2023 performance, with an 8.8% increase in revenue from its CGuard Embolic Prevention Stent System (EPS) sales, which reached $1.56 million. The growth was driven by a significant rise in commercial sales across existing markets, with the company selling 2,734 units of its CGuard EPS stent systems, marking a 4.2% increase.
The company’s gross profit for the third quarter rose by 19.7% to $438,000, underpinned by an increased gross margin of 28.1%. As of September 30, 2023, InspireMD held substantial liquidity with cash and equivalents amounting to $43.0 million.
The positive results were further highlighted by the C-GUARDIANS U.S. IDE clinical trial results presented at VIVA23. The trial demonstrated a major adverse events rate of just 0.95% over thirty days when patients with carotid artery disease were treated with Carotid Artery Stenting (CAS) using CGuard EPS.
In addition to the robust financial performance and promising clinical results, InspireMD also backed the National Coverage Determination by CMS to include both asymptomatic and standard risk patients in CAS coverage. This decision significantly broadens the U.S. CAS addressable market, potentially paving the way for increased usage of InspireMD’s stent-first approach to treating carotid disease.
CEO Marvin Slosman expressed satisfaction with the company’s growth trajectory and hailed the CMS decision as having a transformational impact on their approach to treating carotid disease.
InvestingPro Insights
Drawing from InvestingPro’s real-time data and insightful tips, InspireMD’s financial landscape can be further illuminated. The company’s market capitalization stands at $73.02 million, with a negative P/E ratio of -2.04, indicating that the company is not profitable in the last twelve months, as reflected in InvestingPro Tip 9.
In terms of revenue, InspireMD has experienced a growth rate of 3.48% in the last twelve months as of Q2 2023. This aligns with InvestingPro Tip 4, suggesting a recent slowdown in revenue growth. Despite this, the company has seen a large price uptick over the last six months with a total return of 151.46%, as per InvestingPro Data, corroborating InvestingPro Tip 12.
InvestingPro Tip 0 also highlights that InspireMD holds more cash than debt on its balance sheet, which is in line with the company’s reported liquidity of $43.0 million. This financial strength, coupled with the company’s significant return over the last week, as noted in InvestingPro Tip 3, and the upward revision of earnings by 2 analysts (InvestingPro Tip 1), underscores the potential financial growth of InspireMD.
For a more comprehensive understanding of InspireMD’s financial landscape and additional insights, consider exploring more of the 13 InvestingPro Tips and extensive real-time data available on InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Read the full article here
